451 related articles for article (PubMed ID: 24289293)
21. Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Graves J; Galetta SL; Palmer J; Margolin DH; Rizzo M; Bilbruck J; Balcer LJ
Mult Scler; 2013 Sep; 19(10):1302-9. PubMed ID: 23459567
[TBL] [Abstract][Full Text] [Related]
22. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
Rispens T; Vennegoor A; Wolbink GJ; Polman CH; Killestein J
Mult Scler; 2012 Jun; 18(6):899-901. PubMed ID: 22183929
[TBL] [Abstract][Full Text] [Related]
23. Drug safety evaluation of alemtuzumab for multiple sclerosis.
Willis M; Robertson NP
Expert Opin Drug Saf; 2014 Aug; 13(8):1115-24. PubMed ID: 24935240
[TBL] [Abstract][Full Text] [Related]
24. New management algorithms in multiple sclerosis.
Sorensen PS
Curr Opin Neurol; 2014 Jun; 27(3):246-59. PubMed ID: 24759080
[TBL] [Abstract][Full Text] [Related]
25. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.
Jones DE; Goldman MD
Expert Rev Clin Immunol; 2014 Oct; 10(10):1281-91. PubMed ID: 25148422
[TBL] [Abstract][Full Text] [Related]
26. [Alemtuzumab is a new drug based on monoclonal antibodies for treatment multiple sclerosis: treatment possibilities and risks(review)].
Khasaeva MA; Gorokhova TV; Boĭko AN; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):87-92. PubMed ID: 23675606
[TBL] [Abstract][Full Text] [Related]
27. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
Devonshire V; Phillips R; Wass H; Da Roza G; Senior P
J Neurol; 2018 Nov; 265(11):2494-2505. PubMed ID: 29525836
[TBL] [Abstract][Full Text] [Related]
28. Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
Fox EJ; Wynn D; Coles AJ; Palmer J; Margolin DH;
J Neurol Sci; 2016 Apr; 363():188-94. PubMed ID: 27000249
[TBL] [Abstract][Full Text] [Related]
29. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
Daniels GH; Vladic A; Brinar V; Zavalishin I; Valente W; Oyuela P; Palmer J; Margolin DH; Hollenstein J
J Clin Endocrinol Metab; 2014 Jan; 99(1):80-9. PubMed ID: 24170099
[TBL] [Abstract][Full Text] [Related]
30. Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).
Ziemssen T; Engelmann U; Jahn S; Leptich A; Kern R; Hassoun L; Thomas K
BMC Neurol; 2016 Jul; 16():109. PubMed ID: 27430352
[TBL] [Abstract][Full Text] [Related]
31. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
Ruck T; Bittner S; Wiendl H; Meuth SG
Int J Mol Sci; 2015 Jul; 16(7):16414-39. PubMed ID: 26204829
[TBL] [Abstract][Full Text] [Related]
32. Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia.
Reda G; Maura F; Gritti G; Gregorini A; Binda F; Guidotti F; Piciocchi A; Visco C; Rodeghiero F; Cortelezzi A
Am J Hematol; 2012 Sep; 87(9):936-7. PubMed ID: 22718434
[TBL] [Abstract][Full Text] [Related]
33. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis.
Fox EJ; Rhoades RW
Curr Opin Neurol; 2012 Feb; 25 Suppl():S11-9. PubMed ID: 22398660
[TBL] [Abstract][Full Text] [Related]
34. [Update on Current Care Guideline: Multiple sclerosis].
Remes A; Airas L; Atula S; Färkkilä M; Hartikainen P; Koivisto K; Mäenpää E; Ruutiainen J; Sumelahti ML;
Duodecim; 2015; 131(5):500-1. PubMed ID: 26237913
[TBL] [Abstract][Full Text] [Related]
35. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
Fox EJ; Sullivan HC; Gazda SK; Mayer L; O'Donnell L; Melia K; Lake SL
Eur J Neurol; 2012 Feb; 19(2):307-11. PubMed ID: 21899662
[TBL] [Abstract][Full Text] [Related]
36. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
[TBL] [Abstract][Full Text] [Related]
37. Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis.
Stahnke AM; Holt KM
Ann Pharmacother; 2018 May; 52(5):473-483. PubMed ID: 29232960
[TBL] [Abstract][Full Text] [Related]
38. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
39. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
Coles AJ; Cohen JA; Fox EJ; Giovannoni G; Hartung HP; Havrdova E; Schippling S; Selmaj KW; Traboulsee A; Compston DAS; Margolin DH; Thangavelu K; Chirieac MC; Jody D; Xenopoulos P; Hogan RJ; Panzara MA; Arnold DL;
Neurology; 2017 Sep; 89(11):1117-1126. PubMed ID: 28835403
[TBL] [Abstract][Full Text] [Related]
40. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
